Nurix Therapeutics, Inc. (NASDAQ: NRIX) has enrolled the first patient in the global Phase 3 DAYBreak CLL-306 study, marking a pivotal milestone for its lead candidate bexobrutideg. Conducted under a collaboration with Roche, the registrational trial evaluates bexobrutideg, a targeted protein degrader of Bruton’s tyrosine kinase (BTK), against pirtobrutinib, the current standard of care, in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This head-to-head comparison seeks to redefine treatment outcomes for patients whose disease progressed following prior covalent BTK inhibitor therapy.

The randomized Phase 3 trial is designed to enroll approximately 620 patients globally. Participants will be randomized on a 1:1 basis to receive either bexobrutideg 600 mg orally once per day or pirtobrutinib. The dual primary endpoints are objective response rate (ORR) and progression-free survival (PFS), assessed by an independent review committee. The study is structured to support global regulatory submissions by demonstrating the potential superiority of bexobrutideg relative to the non-covalent BTK inhibitor.

Clinical Development Strategy

Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, and highly selective small-molecule degrader of BTK. Nurix is advancing a broad clinical development program across oncology, immunology, and neurology. In addition to DAYBreak CLL-306, the pipeline includes:

Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, stated that targeted protein degradation offers a fundamentally differentiated approach compared to traditional small molecule inhibition. He emphasized that the trial is designed to test whether this differentiation translates into superior patient outcomes. Paula O’Connor, M.D., chief medical officer, noted that bexobrutideg has demonstrated robust clinical activity with a favorable safety and tolerability profile in relapsed/refractory CLL settings.

What the Numbers Show

The design of DAYBreak CLL-306 highlights a strategic shift toward direct comparative efficacy data. By selecting pirtobrutinib as the comparator, Nurix is challenging the existing non-covalent BTK inhibition standard rather than relying on historical controls or placebo arms. With a target enrollment of approximately 620 patients, the study size suggests sufficient statistical power to detect meaningful differences in ORR and PFS. This approach addresses significant unmet medical needs in patients who have failed covalent BTK inhibitors, positioning bexobrutideg as a potential best-in-class therapy if superiority is demonstrated.

UBS analyst David Dai has maintained a Buy rating on Nurix Therapeutics and raised the price target to $31. The previous target was $23. The firm's updated outlook reflects increased confidence in the company's prospects.

Rating and Target Details

The following table outlines the revised rating and price target for Nurix Therapeutics:

Nurix Therapeutics is listed on NASDAQ under the ticker symbol NRIX.